News

Bayer is shedding its diabetes care division via a deal with long-term partner Panasonic Healthcare Holdings worth 1.02 billion euros.

Organiser PharmaTimes Media invites companies to enter their marketers and teams into this prestigious competition, designed to benchmark talent within organisations and across our industry.

Sanofi and Regeneron’s closely-watched cholesterol buster Praluent (alirocumab) has cleared a key hurdle on the path to market after its approval was backed by US Food and Drug Administration advisors.

NHS England has agreed to invest a whopping £190 million this year in new treatments for hepatitis C, so that patients with liver cirrhosis can finally get NHS access to AbbVie’s new interferon-free antiviral regimen as well as Gilead’s Sovaldi and Harvoni, and thus hope for a cure.

In a stark reminder of the postcode lottery of care that exists in the UK, it is looking likely that patients with chronic plaque psoriasis patients in England and Wales will not be getting NHS access to Celgene’s Otezla while those in Scotland will.

Have you booked your tickets for the PharmaTimes Sales Awards 2015?

Johnson & Johnson is offering up access to its clinical trial data on schizophrenia as part of a new collaborative research project striving to improve understanding of the disease and find better treatments.

Over the next couple of months patients suffering from chronic hives across England and Wales should be offered routine access to Novartis’ Xolair on the National Health Service.

UK patients with type II diabetes could get access to a new combination treatment to control their blood glucose following the nationwide launch of Novo Nordisk’s Xultophy this week.

Eisai has rolled out its thyroid cancer drug Lenvima in the UK just days after European approval, giving patients with advanced forms of the condition a new treatment option shown to improve progression-free survival.

The rate of oesophageal cancer in men has leapt 50% since the 1980s with new cases fast approaching 6,000, according to new statistics from Cancer Research UK.

The pharma industry has paid £207 million to underwrite growth in the branded medicines bill in the first quarter of 2015 as per the UK’s Pharmaceutical Price Regulation Scheme.

More than 40 top researchers from the world’s leading CROs – including Chiltern, Covance, INC Research, Parexel, PPD, PRA Health Sciences and Quintiles – gathered in North Carolina last week to compete in the prestigious PharmaTimes Clinical Researcher of the Year – The Americas competition.

BioMarin Pharmaceuticals has filed experimental Duchenne muscular dystrophy drug drisapersen for approval in Europe, raising hopes for the first approved treatment for the condition.

The Scottish Medicines Consortium has approved funding for four new medicines on NHS Scotland, expanding treatment options for patients with psoriasis, psoriatic arthritis and hepatitis C.